Table des matières
Stage IV non-small cell lung cancer : is there hope for the future ?
Stage IV or advanced NSCLC
Treatment is systemic
Message 1
Level of evidence
The randomised trials
New drugs versus best supportive care (or inactive chemotherapy)
The meta-analyses
Implementation
Eindhoven Cancer Registry Janssen-Heijnen et al, Thorax 59: 602-7; 2004
Message 2
The first-generation drugs
The second-generation drugs
The second generation drugs appear to improve the results when combined with cisplatin
Message 3
Second-generation vs first-generation regimens
High vs low cisplatin dosage
Cisplatin versus carboplatin
The most popular cisplatin-based regimens
Message 4
2001 & 2002
2003
2004
Message 5
The randomised trials are in favour of the use of docetaxel
Alternative drugs
Message 6
Gefinitib, EGFr TK inhibitor
Diapositive PPT
More information …
Message 7
Duration : not until progression !
Number of drugs in the regimen
Guidelines
Meta-analysis Delbaldo, JAMA, 2004
Message 8
Docetaxel as salvage chemotherapy
Conclusions
|